xoma
earns
million
associated
two
partner
developments
rezolute
recent
private
placement
triggers
million
payment
xoma
unrelated
development
partner
initiated
phase
development
undisclosed
asset
triggers
million
milestone
payment
xoma
emeryville
globe
newswire
xoma
corporation
nasdaq
xoma
xoma
company
today
announced
earned
million
payments
two
partners
company
earned
million
accelerated
payments
rezolute
connection
recent
private
placement
continue
advancing
congenital
hyperinsulinism
chi
diabetic
macular
edema
dme
clinical
development
additionally
separate
development
xoma
notified
partner
partner
advanced
undisclosed
asset
xoma
milestone
royalty
portfolio
phase
clinical
development
triggering
million
milestone
payment
congratulate
rezolute
attracting
investors
recent
private
placement
conducted
early
stage
studies
able
get
know
chi
community
patients
families
know
medical
community
needs
approved
treatment
options
help
families
patients
manage
devastating
condition
pleased
rezolute
secured
capital
invest
next
stage
clinical
development
potential
therapeutic
option
chi
patients
stated
jim
neal
chief
executive
officer
xoma
addition
gratifying
see
monetization
strategy
continue
mature
produce
milestone
events
like
phase
advancement
undisclosed
partner
xoma
corporation
xoma
built
significant
portfolio
products
licensed
developed
biotech
pharmaceutical
companies
company
portfolio
programs
spans
multiple
stages
drug
development
process
across
various
therapeutic
areas
many
licenses
result
xoma
pioneering
efforts
discovery
development
antibody
therapeutics
company
business
model
includes
acquiring
additional
milestone
royalty
rights
associated
drug
development
programs
funding
information
visit
safe
harbor
statement
certain
statements
contained
press
release
statements
within
meaning
section
securities
act
section
securities
exchange
act
including
statements
regarding
potential
xoma
portfolio
partnered
programs
licensed
technologies
generating
substantial
milestone
royalty
proceeds
time
creating
additional
value
stockholders
cash
sufficiency
forecast
economic
outlook
potential
impact
pandemic
statements
based
assumptions
may
prove
accurate
actual
results
could
differ
materially
anticipated
due
certain
risks
inherent
biotechnology
industry
including
related
fact
product
candidates
subject
agreements
still
developed
licensees
may
require
substantial
funds
continue
development
may
available
know
whether
continue
viable
market
products
ownership
royalty
interest
therapeutic
product
candidates
royalty
interest
receive
regulatory
approval
licensees
able
market
impact
global
economy
result
pandemic
potential
risks
xoma
meeting
expectations
described
detail
xoma
recent
filing
form
sec
filings
consider
risks
carefully
considering
xoma
prospects
statement
press
release
represents
xoma
views
date
press
release
relied
upon
representing
views
subsequent
date
xoma
disclaims
obligation
update
statement
except
required
applicable
law
explanatory
note
references
portfolio
press
release
refer
strictly
milestone
royalty
rights
associated
basket
drug
products
development
references
assets
press
release
refer
strictly
milestone
royalty
rights
associated
individual
drug
products
development
references
royalties
royalty
rates
strictly
refer
future
potential
payment
streams
regardless
whether
technically
defined
royalties
underlying
contractual
agreement
rates
referenced
herein
subject
potential
future
contractual
adjustments
date
assets
xoma
portfolio
investigational
compounds
assurance
compounds
approved
regulatory
authorities
commercially
available
investor
contact
juliane
snowden
oratorium
group
llc
jsnowden
media
contact
kathy
vincent
kv
consulting
management
kathy
